[Minutes, Advisory Committee to the Director GP-160 Meeting (1992: Bethesda, Maryland)]

132
1 has been brought up is that now is not the issue
2 because if we decided right now on the exact design of
3 the trial and just what we wanted to do, months of
4 effort -- and I don't care how fast we move forward or
5 whatever, or what we want to do. The reality is that
6 months of effort will go into designing and coming up
7 with the infrastructures to implement this trial.
8 So what I would propose, I believe that we
9 should design this trial as quickly as we possibly can
10 if the Army is going to cooperate with us, of course.
11 But maybe we'll be leaving things like
12 immunogens, dose, and so forth blank while we design
13 the trial because data are coming in, and we will know
14 more at another point. I think probably the choice of
15 immunogens will be the last thing we do before the
16 trial starts. So I think that's important to
17 consider.
18 There are problems, however. Everybody,
19 I think, is going to be tempted, and me as well, to
20 wait for 209 and 214, which are the trials that were
21 described earlier, to choose immunogens.
22 I'm afraid we won't have that luxury. If

NEAL R. GROSS
COURT REPORTERS AND TRANSCRIBERS
1323 RHODE ISLAND AVENUE, N.W.
[phone] WASHINGTON, D.C. 20005 [phone]